<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>AmitisGen TECH Dev Group</PublisherName>
				<JournalTitle>Personalized and Precision Medicine Journal</JournalTitle>
				<Issn>3115-7874</Issn>
				<Volume>8</Volume>
				<Issue>28</Issue>
				<PubDate PubStatus="epublish">
					<Year>2023</Year>
					<Month>03</Month>
					<Day>22</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Treatment of Rheumatoid Arthritis Based on Personalized Medicine: a New Approach in Rheumatology</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>35</FirstPage>
			<LastPage>45</LastPage>
			<ELocationID EIdType="pii">702084</ELocationID>
			
<ELocationID EIdType="doi">10.22034/pmj.2023.702084</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Hossein</FirstName>
					<LastName>Amin-Anaraki</LastName>
<Affiliation>Biotechnology Research Center, Islamic Azad University, East-Tehran Branch, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Saber</FirstName>
					<LastName>Kabiri-Samani</LastName>
<Affiliation>Young Researchers and Elite Club, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran.</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2022</Year>
					<Month>11</Month>
					<Day>22</Day>
				</PubDate>
			</History>
		    <Abstract>In the twenty-first century, there still needs more clarity on rheumatoid arthritis (RA). Rheumatoid arthritis is a widespread but heterogeneous illness with a broad range in its history, clinical symptoms, and response to therapy. It is now known that prevention of joint destruction, functional impairment, and a poor disease prognosis depends on early, correct diagnosis and starting therapy with disease-modifying drugs (DMARDs), among which methotrexate (MTX) remains the gold standard in the treatment of RA. Early rheumatoid arthritis diagnosis is crucial since it enables a speedier start to primary therapy. Pharmacogenetic and pharmacogenomic research, which aid in identifying a patient’s genetic profile, may bring personalized treatment closer to reality. Identifying disease-specific genes while the organism’s resistance to them is still intact should be made feasible by further study into RA.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Personalized Medicine</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Rheumatoid arthritis</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Biomarkers</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Genetic test</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.pmjournal.ir/article_702084_6be12e81390b676a7f3235eeffdd3232.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
